HER2 Support Group Forums - View Single Post

gdpawel · 11-16-2009, 09:20 AM

As far as I know, there hasn't been any studies of taxane-induced neuropathy. However, recently, there is a SWOG trial aimed at studying neuropathy. It is a Phase III trial that just started in September 2009 that will involve 380 participants and is available at 180 locations.

Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy

http://clinicaltrials.gov/ct/show/NCT00775645

Unfortunately, it excludes those with prior taxane therapy! I came across a Yale School of Medicine study that apparently found a molecular basis for the peripheral pain caused by taxanes. It appears to be caused when the drug binds to a protein and initiates improper calcium signaling. This response leads to side effects such as acute hypersensitivity, slower heart rhythms, tingling, numbness, and other symptoms (PNAS 104: 11103-11108 June 20, 2007)

11-16-2009, 09:20 AM	#3
gdpawel Senior Member Join Date: Aug 2006 Location: Pennsylvania Posts: 1,080	Preventing neuropathy in breast cancer patients undergoing chemotherapy? As far as I know, there hasn't been any studies of taxane-induced neuropathy. However, recently, there is a SWOG trial aimed at studying neuropathy. It is a Phase III trial that just started in September 2009 that will involve 380 participants and is available at 180 locations. Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy http://clinicaltrials.gov/ct/show/NCT00775645 Unfortunately, it excludes those with prior taxane therapy! I came across a Yale School of Medicine study that apparently found a molecular basis for the peripheral pain caused by taxanes. It appears to be caused when the drug binds to a protein and initiates improper calcium signaling. This response leads to side effects such as acute hypersensitivity, slower heart rhythms, tingling, numbness, and other symptoms (PNAS 104: 11103-11108 June 20, 2007)